Cite
HARVARD Citation
Rudin, C. et al. (n.d.). Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet oncology. 18 (1), pp. 42-51. [Online].